Comment on “Intravitreal dexamethasone implants for diabetic macular edema”

December 2018, Volume 11, Issue 12, p. 2029-2032
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting

December 2018, Volume 196, p. 208–209
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Comment on “Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration”

November 2018, Volume 11, Issue 11, p. 1884-1886
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Clinical Features of Central Serous Chorioretinopathy With Type 1 Choroidal Neovascularization

November 2018, Volume 195, p. 245–246
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy

October 2018, Volume 10, Issue 10, pp.74701-74702
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the united states

October 2018, Volume 10, Issue 10, pp.74665-74666
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Re: Li et al.: Long-term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti-Vascular Endothelial Growth Factor

October 2018, Volume 2, Issue 10, p. e13-e14
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Guidelines on diabetic eye care. the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings

September 2018, Volume 8, Issue 9, pp. 22645-22646
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Vision Outcomes Following Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice

September 2018, Volume 193, p. 253–254
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Comment on “Management strategies in malignant glaucoma secondary to antiglaucoma surgery”

August 2018, Volume 11, Issue 8, p. 1433-1434
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Correspondence

August 2018, Volume 38, Issue 8, p. e69–e71
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

What We Have Learned From the Ocular Hypertension Treatment Study

August 2018, Volume 192, p. 248–249
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy

August 2018, Volume 256, Issue 8, pp. 1551–1552
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy

July, 2018, Volume 10, Issue 7, pp. 71192-71193
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the crystal study

July 2018, Volume 10, Issue 7, pp. 71828-71829
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Ocular hypertension in patients with central/hemicentral retinal vein occlusions: cumulative prevalence and management

July 2018, Volume 11, Issue 7, pp. 1173-1178
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success

July 2018, Volume 256, Issue 7, pp. 1353–1354
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment

May 2018, Volume 256, Issue 5, pp. 1035–1037
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Outcomes of Patients Initially Treated with Intravitreal Bevacizumab for Central Retinal Vein Occlusion: Long-Term Follow-Up

May 2018, Volume 33, Issue 3, p.318-319
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany. Twelve-month outcomes of Perseus

April 2018, Volume 10, Issue 4, pp. 68602-68603
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Letter to the Editor: Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial

March 2018, Volume 49, Issue 3, p. 160
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Re: Khurana et al.: Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study (Ophthalmol Retina. 2017)

March 2018, Volume 2, Issue 3, p. e5–e6
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy

March 2018, Volume 256, Issue 3, pp. 627–629
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania

Bun venit!

Cu entuziasm și profesionalism, Dr. Dan CĂLUGĂRU a format o echipă bine pregătită, care având la dispoziție tehnică medicală performantă, ajută la rezolvarea problemelor oftalmologice, punând întotdeauna accent pe confortul și siguranța pacienților, oferind servicii oftamologice complete la standarde înalte de calitate, atât prin experiența profesională cât și ca nivel al dotării cu aparatură. Echipa beneficiază de suportul și experiența Prof. Univ. Dr. Mihai Călugăru.

În clinica noastră se tratează peste 3000 de pacienți anual, număr în permanentă creștere, având în vedere progresul științific și tehnic de care echipa Dr. Călugăru este mereu preocupată.

Echipamentele noaste sunt furnizate de către producători consacrați în domeniu: Alcon (S.U.A), Bausch & Lomb (SUA), Blanco (Germania), Brumaba (Germania), Carl Zeiss Meditec (Germania), Spacelabs (S.U.A), Getinge (Suedia), Tomey (Japonia), Melag (Germania), Nidek (Japonia), Briot (Belgia).

Pentru operațiile de reducere a dioptriilor cu laser excimer (Lasek, Prk) nu este nevoie de analize. Pentru toate celelalte intervenții chirurgicale analizele sunt obligatorii.

Analizele necesare pentru operație:

  • Hemoleucograma
  • Coagulograma
  • Glicemie
  • Uree
  • VSH
  • AST
  • ALT
  • Bilirubina totală
  • HVB
  • HVC
  • HIV
  • Consult cardiologic
  • EKG

Pentru a reuși vindecarea unui număr cât mai mare de pacienți echipa Dr. Călugăru colaborează cu mai mulți medici specializați în oftalmologie, opticieni și optometriști, cât și cu medicii de familie din zonele învecinate.